With over 8 billion people and only 4 million pharmacists worldwide, medication safety has reached crisis levels. Studies show that 53% of avoidable harm is linked to medication-related issues, and in the UK alone, 377 million medication errors occur annually.
Aspirin AI, created by UK-based DrGuide.net and led by senior professional pharmacists Salman Chishti and Serge Haykin, has launched as the world’s first AI Pharmacist. Built specifically for doctors, nurses, pharmacists, carers, patients, and students, Aspirin AI delivers instant, pharmacist-grade answers across 19 critical medicine data points, including:
Name & Classification
Indications & Dosing
Contraindications & Warnings
Interactions & Patient Counselling
Use in Pregnancy, Children, Elderly, Kidney & Liver disease
“Pharmacists are the only qualified experts in the safe use of medicines, yet we are far too few. No one should suffer because clear medicine information isn’t available at the right moment. Aspirin AI is our answer – a tool to empower every professional, patient, and family to make safer medicine decisions instantly.” said Salman Chishti, Co-Founder of DrGuide.net.
Since its initial Android release in June 2025 (over 300+ organic downloads without paid promotion), Aspirin AI has now launched on iOS (August 2025) and Web – making it globally accessible.
Aspirin AI is calling on healthcare professionals worldwide – doctors, nurses, pharmacists, carers, and students – to join its mission to reduce the global pandemic of medication errors.
Availability:
iOS: https://apps.apple.com/gb/app/aspirin-ai/id6746511623
Android: https://play.google.com/store/apps/details?id=appdrguidenet.wpapp
Web: https://DrGuide.net
Salman Chishti
London, UK
https://drguide.net/about-us/
CKR House. Dartford. DA1 1RZ. England. UK
DrGuide.net is a UK-based digital health platform dedicated to improving global medicine safety through accessible, accurate, and instant information. Founded by pharmacists Salman Chishti and Serge Haykin, DrGuide.net builds tools for clinicians, patients, and families to reduce harm from medicines and improve outcomes worldwide.
This release was published on openPR.